MarketBeat
18 Nov 2026, 03:13 UTC · 6h ago
ACADIA Pharmaceuticals Eyes Deals as DAYBUE Growth Fuels Revenue Surge
Impact · against what's priced in
ACADIA's raised DAYBUE guidance and strong cash position provide a solid baseline, but the upcoming NUPLAZID IP appeal creates a significant binary risk. While commercial growth is strong, the potential for accelerated generic entry introduces a new downside catalyst not previously quantified in guidance.
- ACAD+0.20
No priced-in read yet
- In context
The potential for a ruling on NUPLAZID intellectual property 'within weeks' introduces an immediate binary risk to the $202M revenue stream that offsets the positive momentum from raised DAYBUE guidance ($505M-$520M).
Read from the article alone





